170487-39-5

Basic information

• Product Name: 2-Pyridinecarbonitrile,4-methyl-,1-oxide(9CI)
• Synonyms: 2-Pyridinecarbonitrile,4-methyl-,1-oxide(9CI)
• CAS NO: 170487-39-5
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Product Categories: NITRILE;PYRIDINE
• Mol File: 170487-39-5.mol

Chemical Properties

• Boiling Point: 393.5°C at 760 mmHg
• Flash Point: 191.8°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 2.13E-06mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 2-Pyridinecarbonitrile,4-methyl-,1-oxide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarbonitrile,4-methyl-,1-oxide(9CI)(170487-39-5)
• EPA Substance Registry System: 2-Pyridinecarbonitrile,4-methyl-,1-oxide(9CI)(170487-39-5)

Safety Data

• Hazardous Substances Data: 170487-39-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H6N2O/c1-6-2-3-9(10)7(4-6)5-8/h2-4H,1H3

Upstream product

• 1620-76-4 2-Cyano-4-methylpyridin 
• 1003-67-4 4-methylpyridine-1-oxide 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 

Downstream Products

• 209858-74-2 2-cyano-6-chloro-4-methyl pyridine 
• 53547-60-7 4-methyl-2-pyridinecarbaldehyde 

Relevant articles and documents

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H-1,2,4-triazol-3-one, by Fragment-Based Drug Design

This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton's tyrosine kinase inhibitor, which ultimately became the Takeda Pharmaceuticals clinical candidate TAK-020. Describe

PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof

Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment of neurodegenerative disorders or neurotoxic injuries utilizing them, wherein the substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts have the formula: STR1 wherein: R1, R2, R3, R4, R5, R6, R7, X and p are as defined in the specification.